Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
SynopsisF

Health Canada to seek public input on drugs

Laura Eggertson
CMAJ March 15, 2005 172 (6) 733; DOI: https://doi.org/10.1503/cmaj.050211
Laura Eggertson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading
  • © 2005 CMA Media Inc. or its licensors

Health Minister Ujjal Dosanjh has promised to open up Canada's drug approval process to allow public comment on pharmaceutical company submissions and on postmarketing experiences.

Figure

Figure. Federal Health Minister Ujjal Dosanjh promises more transparency on drugs. Photo by: Canapress

The changes to Health Canada's drug approval process — which has long been criticized by public interest groups as being too closed — stem from the department's experience with rofecoxib (Vioxx) and other COX-2 inhibitors, Dosanjh said during a conference call with a few reporters on Feb. 15.

“Canadians have and must continue to have confidence in Health Canada to act in their best interests,” Dosanjh said. “One of the means to accomplish this is to ensure opportunities for public interest before regulatory decisions are made.That means before approval and in the post-market actions.”

Dosanjh's proposed changes include creating a permanent advisory panel modelled on the one the US Food and Drug Administration (FDA) set up to review the safety of COX-2 inhibitors.

“I believe a uniquely Canadian model can be developed,” Dosanjh said. “This model must take into account the needs of the patients [and] consumers, be supportive of the practitioners and be built on evidence and scientific expertise.”

Dosanjh scheduled his conference the same day the FDA announced its new Drug Safety Oversight Board. That board, consisting of FDA and other government scientists, will consult with medical experts and patient groups to assess post-marketing safety data. The board was created in response to public criticism — and mounting lawsuits — alleging that the FDA ignored the warnings from its own scientists about the potential risks of rofecoxib and other drugs. Merck withdrew rofecoxib from sale in both Canada and the US on Sept. 30.

The FDA is also creating a Drug Watch Web page to post emerging data about new drugs as soon as potential risks are raised. instead of waiting for the FDA reaction.

In Ottawa, Dosanjh said he will ask the all-party Standing Committee on Health to advise the department on a new, more open process, and on a forum for public input. He also indicated he was not “unalterably opposed” to creating an independent agency to review drug safety.

The minister expressed surprise when reporters informed him they cannot currently get access to documents related to Health Canada's deliberations over rofecoxib and other COX-2 inhibitors.

“You don't have them now?” Dosnajh asked. He said that all the documents, except those that violate individual privacy or proprietary information, should be released.The FDA has posted comparable documents online.

The Canadian Health Coalition, a public-interest group that has been highly critical of Health Canada's secrecy, described Dosnjah's remarks as “encouraging.”

“We have a minister who's not, I believe, captured by the industry,” says executive director Mike McBane. “Can he wrestle the public agency back into [serving] the public interest? That's the political challenge we're facing.”

The all-party Health Committee issued a report last winter pushing for more transparency. “The status quo is unacceptable,” says McBane. “We have to end the secrecy and stop jeopardizing public health and people's lives.”

In related news, the FDA's advisory panel on COX-2 inhibitors recommended that rofecoxib, celecoxib (Celebrex) and valdecoxib (Bextra) stay on the market, albeit with Black Box warnings about possible cardiac complications.

Ten Health Canada scientists and physicians in consultation with a panel of 9 external experts are conducting their own review of the COX-2 inhibitors. The results are due at the end of March.

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 172 (6)
CMAJ
Vol. 172, Issue 6
15 Mar 2005
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Health Canada to seek public input on drugs
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Health Canada to seek public input on drugs
Laura Eggertson
CMAJ Mar 2005, 172 (6) 733; DOI: 10.1503/cmaj.050211

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Health Canada to seek public input on drugs
Laura Eggertson
CMAJ Mar 2005, 172 (6) 733; DOI: 10.1503/cmaj.050211
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Applying the 2005 Canadian Hypertension Education Program recommendations: 4. Managing uncomplicated hypertension
  • A newborn requiring selective bronchial intubation
  • Does β-blocker prophylaxis improve survival after major noncardiac surgery?
Show more Synopsis

Similar Articles

Collections

  • Topics
    • Canadian government
    • Drugs: adverse reactions

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire